Management of chronic myeloid leukemia in 2023 – common ground and common sense

Management of chronic myeloid leukemia in 2023 – common ground and common sense

Abstract With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic phase (CML-CP), imatinib and the three second-gener...

Full description

Bibliographic Details
Main Authors: Jayastu Senapati, Koji Sasaki, Ghayas C. Issa, Jeffrey H. Lipton, Jerald P. Radich, Elias Jabbour, Hagop M. Kantarjian
Format: Article
Language:English
Published: Nature Publishing Group 2023-04-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00823-9

Internet

https://doi.org/10.1038/s41408-023-00823-9

Similar Items